We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, a... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. Show more
Tesla (NASDAQ:TSLA) – Tesla’s sales in China increased by 19.2% in September, totaling over 72,000 electric vehicles sold, its best performance of the year. Deliveries of locally...
October 2, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as...
Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials PR Newswire INDIANAPOLIS, Oct. 2, 2024 Indiana...
New data show Lilly's EBGLYSSβ’ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis PR...
Lilly's Kisunlaβ’ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease PR Newswire INDIANAPOLIS, Sept. 24, 2024 Japan is the second major market where...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 40.22 | 4.50977753857 | 891.84 | 932.24 | 891.84 | 2101853 | 914.15333591 | CS |
4 | 1.81 | 0.194571351787 | 930.25 | 939.86 | 863.65 | 2644812 | 907.53146915 | CS |
12 | 68.29 | 7.90603980226 | 863.77 | 972.53 | 747.55 | 3033713 | 887.41887284 | CS |
26 | 171.56 | 22.5588428665 | 760.5 | 972.53 | 718.3 | 2913025 | 858.14192545 | CS |
52 | 321.07 | 52.5491415571 | 610.99 | 972.53 | 547.61 | 3012687 | 757.35500936 | CS |
156 | 695.05 | 293.257668453 | 237.01 | 972.53 | 231.87 | 2979190 | 487.33968724 | CS |
260 | 823.69 | 760.071975639 | 108.37 | 972.53 | 101.36 | 3255752 | 342.15306298 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions